AFE (0.63–2.50 g/kg) significantly prevented the formation of acid reflux esophagitis, reduced
the formation of ethanol-induced acute gastric lesions, suppressed the development of gastric lesions in
response to serotonin, and accelerated the healing of acetic acid-induced chronic gastric ulcer in rats with
equal potency to those obtained by standard antisecretory agents (ranitidine and lansoprazole). AFE also
significantly inhibited gastric acid secretion and pepsin activity in pylorus ligated rats. Additionally, AFE
strongly increased the gastrointestinal transit of charcoal meal with a higher potency than cisapride. Pure
scopoletin, when compared at the same equivalent dose containing in AFE, possessed similar antiulcer
and antisecretory properties to that of AFE although it exerted a less prokinetic activity than AFE